|
Real-time Estimate
Cboe Europe
13:09:20 27/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 1,881.50 GBX | -0.95% |
|
-1.46% | +3.48% |
| 08-26 | GSK's ViiV Healthcare Says US FDA Approves Tivicay PD for Pediatric HIV Patients | MT |
| 08-25 | GSK plc : Deutsche Bank remains Neutral | ZD |
Company Valuation: GSK plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 80,458 | 58,381 | 59,112 | 54,944 | 73,201 | 76,113 | - | - |
| Change | - | -27.44% | 1.25% | -7.05% | 33.23% | 3.98% | - | - |
| Enterprise Value (EV) 1 | 100,296 | 75,578 | 74,152 | 68,039 | 87,654 | 95,951 | 93,173 | 90,178 |
| Change | - | -24.65% | -1.89% | -8.24% | 28.83% | 9.47% | -2.9% | -3.21% |
| P/E | 18.6x | 3.93x | 11.9x | 21.3x | 12.9x | 14.4x | 11.8x | 11x |
| PBR | 5.34x | 5.47x | 4.4x | 4.02x | - | 4.64x | 4.06x | 3.57x |
| PEG | - | 0x | -0.2x | -0.4x | 0x | -2.3x | 0.5x | 1.59x |
| Capitalization / Revenue | 2.36x | 1.99x | 1.95x | 1.75x | 2.24x | 2.24x | 2.14x | 2.08x |
| EV / Revenue | 2.94x | 2.58x | 2.45x | 2.17x | 2.68x | 2.83x | 2.62x | 2.46x |
| EV / EBITDA | 8.85x | 7.23x | 6.37x | 6.36x | 7.77x | 8.37x | 7.6x | 7.1x |
| EV / EBIT | 11.4x | 9.27x | 8.44x | 7.44x | 8.96x | 9.32x | 8.44x | 7.83x |
| EV / FCF | 22.6x | 12.1x | 13.6x | 13x | 13.7x | 17.3x | 16.1x | 13.3x |
| FCF Yield | 4.42% | 8.28% | 7.36% | 7.67% | 7.32% | 5.78% | 6.22% | 7.54% |
| Dividend per Share 2 | 1 | 0.6125 | 0.58 | 0.61 | 0.66 | 0.6958 | 0.7495 | 0.7831 |
| Rate of return | 4.98% | 4.26% | 4% | 4.53% | 3.62% | 3.66% | 3.95% | 4.12% |
| EPS 2 | 1.082 | 3.662 | 1.216 | 0.632 | 1.411 | 1.323 | 1.616 | 1.728 |
| Distribution rate | 92.4% | 16.7% | 47.7% | 96.5% | 46.8% | 52.6% | 46.4% | 45.3% |
| Net sales 1 | 34,114 | 29,324 | 30,328 | 31,376 | 32,667 | 33,936 | 35,515 | 36,639 |
| EBITDA 1 | 11,330 | 10,449 | 11,635 | 10,693 | 11,278 | 11,464 | 12,256 | 12,693 |
| EBIT 1 | 8,806 | 8,151 | 8,786 | 9,148 | 9,783 | 10,298 | 11,044 | 11,519 |
| Net income 1 | 4,385 | 14,956 | 4,928 | 2,575 | 5,716 | 5,436 | 6,484 | 6,933 |
| Net Debt 1 | 19,838 | 17,197 | 15,040 | 13,095 | 14,453 | 19,838 | 17,060 | 14,065 |
| Reference price 2 | 20.08 | 14.38 | 14.50 | 13.46 | 18.24 | 19.00 | 19.00 | 19.00 |
| Nbr of stocks (in thousands) | 4,006,383 | 4,060,999 | 4,076,145 | 4,080,519 | 4,012,126 | 4,007,011 | - | - |
| Announcement Date | 09/02/22 | 01/02/23 | 31/01/24 | 05/02/25 | 04/02/26 | - | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 14.36x | 2.83x | 8.37x | 3.66% | 103B | |
| 33.86x | 12.29x | 24.9x | 0.58% | 1,060B | |
| 30.03x | - | - | 1.99% | 651B | |
| 33.56x | 7.77x | 16.15x | 2.61% | 465B | |
| 20.52x | 4.87x | 12.06x | 2.71% | 365B | |
| 22.43x | 5.77x | 14.31x | 2.77% | 300B | |
| 21.39x | 4.38x | 12.52x | 2.01% | 258B | |
| 27.85x | 7.18x | 12.75x | 2.29% | 238B | |
| 13.86x | 4.91x | 10.27x | 3.71% | 210B | |
| -45.25x | 6.53x | 25.49x | 2.23% | 184B | |
| Average | 17.26x | 6.28x | 15.20x | 2.46% | 383.39B | |
| Weighted average by Cap. | 24.38x | 8.01x | 17.77x | 1.98% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GSK Stock
- Valuation GSK plc
Select your edition
All financial news and data tailored to specific country editions
